Navigation Links
Southern Research Expands Sales and Marketing Agreement with Absorption Systems to Service European Market
Date:11/9/2007

BIRMINGHAM, Ala. and EXTON, Pa., Nov. 9 /PRNewswire-USNewswire/ -- Southern Research Institute and Absorption Systems, LP today announced that they have expanded their joint marketing agreement to allow Absorption Systems to represent Southern Research in European biotechnology and pharmaceutical markets. Ten months ago, the two organizations announced that they had signed a joint marketing agreement to collaborate in marketing contract research services in the areas of toxicology and bioanalytical services to biotechnology and pharmaceutical clients in the U.S.

The agreement expands this partnership so Absorption Systems will provide marketing and sales representation of Southern Research in Europe. Both companies will continue to provide critical preclinical contract research support to the biotechnology and pharmaceutical industries. Financial terms of the agreement were not announced.

"Our international business has expanded dramatically in the past 18 months, so this agreement with Absorption Systems will allow us to enhance our support to those clients, while continuing to expand our geographic reach," said Chaarles G. Fogelgren, director of Business Operations for the Drug Development Division at Southern Research.

"We are excited about expanding our relationship with Southern Research. Adding their capabilities in toxicology, cancer efficacy and anti-infectives to our capabilities in ADME and bioanalysis will provide a better outsourcing solution for our clients," said Patrick Dentinger, president and CEO of Absorption Systems.

The European sales and marketing representation also signals an expansion of Southern Research's dedicated sales force. In the past year, Southern Research has established a U.S.-based geographic sales force (http://www.southernresearch.org/bd-territories.html) and is moving to expand upon this success.

About Absorption Systems, LP

Founded in 1996, Absorption Systems, LP (ASLP) focuses on performing assays that can predict the Absorption, Distribution, Metabolism, and Excretion (ADME) of small molecules using a variety of in vitro, in situ, and in vivo models. ASLP supports these assays with state-of-the-art bioanalytical capabilities and preclinical formulation services. For more information, visit http://www.absorption.com.

About Southern Research Institute

Southern Research Institute is a not-for-profit organization that conducts basic and applied research in the areas of preclinical drug discovery and development. To date, Southern Research has discovered a record six cancer drugs that have received FDA-approval, with another six compounds currently in late-stage preclinical development or clinical trials. Southern Research has evaluated 50 percent of all other FDA-approved cancer drugs currently on the market. For more information, please visit http://www.SouthernResearch.org.

Media Contacts

Rhonda Jung 205-581-2317

Southern Research

jung@southernresearch.org

Risa Burgess 781-684-0770

Schwartz Communications

southern@schwartz-pr.com


'/>"/>
SOURCE Southern Research Institute
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Biomaxx Systems Inc. Selected as Technical Consultant By Southern Cross Agricultural Developments
2. Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals
3. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
6. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
7. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
8. eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th
9. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
10. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
11. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... 2017 Aethlon Medical, Inc. (Nasdaq: ... that validated the ability of the Aethlon Hemopurifier® to ... mortality in immune-suppressed sepsis patients and also contribute to ... objective of the study was to validate the ... (EBV) and Herpes Simplex virus 1 (HSV1) by the ...
(Date:2/22/2017)... SAN DIEGO , Feb. 22, ... (OTCQB:CELZ) announced today expansion of its translational research ... product through establishment of laboratory facilities in San ... the San Diego BioLabs facility, a biotechnology incubator ... and Sanofi. In November 2016, the ...
(Date:2/21/2017)... Feb. 21, 2017 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the ... results for the three months ended December 31, 2016. ... life sciences and diagnostics company that develops and commercializes proprietary ... ... build on the commercial milestones achieved in fiscal 2016," said ...
(Date:2/21/2017)... Basel, Switzerland (PRWEB) , ... February 21, 2017 ... ... for biopharmaceutical and biotech research and development (R&D), today announced the establishment of ... headed by Managing Director Kevin Teburi, a recognized expert in life science informatics. ...
Breaking Biology Technology:
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
(Date:1/30/2017)...   Invitae Corporation (NYSE: NVTA ... today announced that it will report its fourth quarter ... on Monday, February 13, 2017, and Invitae,s management team ... p.m. Eastern / 1:45 p.m. Pacific. ... financial results, guidance, and recent developments and will spend ...
(Date:1/24/2017)... PHILADELPHIA , Jan. 24, 2017  It ... a baby,s sock that monitors vital signs and ... instance, an infant,s oxygen saturation level drops. But ... undue alarm to parents, with no evidence of ... "These devices are marketed aggressively to parents of ...
Breaking Biology News(10 mins):